|Bid||0.0000 x 1100|
|Ask||0.0000 x 1000|
|Day's Range||1.4801 - 1.5200|
|52 Week Range||0.7200 - 2.6900|
|Beta (5Y Monthly)||2.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2023 - Nov 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.17|
Subscribe to Yahoo Finance Plus to view Fair Value for AQST
In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.52, marking a -0.65% move from the previous day.
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the development timeline and pathway for its oral epinephrine product candidate, Anaphylm™. As previously disclosed, Aquestive submitted its revised protocol for the proposed pivotal PK clinical trial to the Food an